Molecular biology and gene therapy in the treatment of chronic pain

Neurosurgery Clinics of North America

Volumn 14, Issue 3, 2003, Pages 419-435

  Garrity Moses, Mary E ^a   Liu, James K ^a   Boulis, Nicholas M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANGIOSTATIN; ASPARTYL ACYLASE; BONE MORPHOGENETIC PROTEIN; BRAIN DERIVED GROWTH FACTOR; CARBOXYLYASE; DEXAMETHASONE; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOXYCYCLINE; GALANIN; GALANIN DERIVATIVE; GLUTAMATE DECARBOXYLASE; GREEN FLUORESCENT PROTEIN; HYBRID PROTEIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; LENTIVIRUS VECTOR; LIPOSOME; MANGANESE SUPEROXIDE DISMUTASE; NAKED DNA; NEURITE PROMOTING FACTOR; NEURON SPECIFIC ENOLASE; PLASMID DNA; POLYETHYLENEIMINE; POLYMER; PREPROGALANIN; PROOPIOMELANOCORTIN; RECOMBINANT ENZYME; RECOMBINANT INTERLEUKIN 12; RETROVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CELL TRANSFORMATION; CHRONIC PAIN; CLINICAL TRIAL; DOPAMINE METABOLISM; ENDOMETRIOSIS; GENE CASSETTE; GENE OVEREXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSFECTION; GLYCOGEN STORAGE DISEASE TYPE 4; HERPES SIMPLEX VIRUS 1; HUMAN; LONG TERMINAL REPEAT; NEUROBLASTOMA CELL; NEUROMODULATION; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARKINSONISM; PELVIS PAIN SYNDROME; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; SECOND MESSENGER; SYNAPSE; TRANSGENE; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM; VIRUS GENOME; VIRUS RECOMBINANT;

EID: 0038710474     PISSN: 10423680     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1042-3680(03)00008-1     Document Type: Review

References (103)

1. Capecchi M. High efficiency transformation by direct microinjection of DNA into cultured mammalian cells. Cell 1980;22(Part 2):479-88.
2. Cartier R, Reszka R. Utilization of synthetic peptides containing nuclear localization signals for nonviral gene transfer systems. Gene Ther 2002;9:157-67.
3. Tseng W, Haselton F, Giorgio T. Mitosis enhances transgene expression of plasmid delivered by cationic liposomes. Biochim Biophys Acta 1999;1445:53-64.
4. Wilke M, Fortunati E, van den Broek M, Hoogeveen A, Scholte B. Efficacy of a peptide-based gene delivery system depends on mitotic activity. Gene Ther 1996;3:1133-42.
5. Wolff J, Malone R, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247(Part 1):1465-8.
6. Lin C, Yang L, Lee T, et al. Electroporation-mediated pain-killer gene therapy for mononeuropathic rats. Gene Ther 2002;9:1247-53.
7. Yang N, Burkholder J, Roberts B, Martinell B, McCabe D. In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment. Proc Natl Acad Sci USA 1990;87:9568-72.
8. Felgner P, Gadek T, Holm M, et al. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987;84:7413-7.
9. Caplen N, Alton E, Middleton P, et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995;1:39-46.
10. Gao X, Huang L. Potentiation of cationic liposome-mediated gene delivery by polycations. Biochemistry 1996;35:1027-36.
11. Huang L, Farhood H, Serbina N, Teepe A, Barsoum J. Endosomolytic activity of cationic liposomomes enhances the delivery of human immunodeficiency virus-1 trans-activator protein (TAT) to mammalian cells. Biochem Biophys Res Commun 1995;217:761-8.
12. Hui S, Langner M, Zhao Y, Ross P, Hurley E, Chan K. The role of helper lipids in cationic liposome-mediated gene transfer. Biophys J 1996;71:590-9.
13. Boussif O, Lezoualc'h F, Zanta M, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995;92:7297-301.
14. Yant S, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay M. Somatic integration and long-term transgene expression in normal and hemophilic mice using a DNA transposon system. Nat Genet 2000;25:35-41.
15. Kozarsky K, Wilson J. Gene therapy: adenovirus vectors. Curr Opin Genet Dev 1993;3:499-503.
16. Neve R. Adenovirus vectors enter the brain. Trends Neurosci 1993;16:252-3.
17. Lawrence M, McLaughlin J, Sun G, et al. Herpes simplex viral vectors expressing Bcl-2 are neuroprotective when delivered after a stroke. J Cereb Blood Flow 1997;17:740-4.
18. Breakefield X, DeLuca N. Herpes simplex virus for gene delivery to neurons. New Biol 1991;3:203-18.
19. Peel A, Klein R. Adeno-associated virus vectors activity and applications in the CNS. J Neurosci Methods 2000;98:95-104.
20. Blomer U, Naldini L, Kafri T, Trono D, Verma I, Gage F. Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol 1997;71:6641-9.
21. Hannas-Djebbara Z, Didier-Bazs M, Sacchettoni S. et al. Transgene expression of plasmid DNAs directed by viral or neural promoters in the rat brain. Brain Res Mol Brain Res 1997;46:91-9.
22. Yin D, Zhu L, Schimke R. Tetracycline-controlled gene expression system achieves high-level and quantitative control of gene expression. Anal Biochem 1996;235:195-201.
23. Gallia G, Khalili K. Evaluation of an autoregulatory tetracycline regulated system. Oncogene 1998;16:1879-84.
24. Mizuguchi H, Hayakawa T. The tet-off system is more effective than the tet-on system for regulating transgene expression in a single adenovirus vector. J Gene Med 2002;4:240-7.
25. Qin M, Lee E, Zankel T, Ow D. Site-specific cleavage of chromosomes in vitro through Cre-Lox recombination. Nucleic Acids Res 1995;23:1923-7.
26. Davidson B, Doran S, Shewach D, Latta J, Hartman J, Rowwsler B. Expression of E-coli β-galactosidase and rate HPRT in the CNS of Macaca mulatta following adenoviral mediated gene transfer. Exp Neurol 1994;125:258-67.
27. Baumgartner B, Shine H. Targeted transduction of CNS neurons with adenoviral vectors carrying neurotrophic factor genes confers neuroprotection that exceeds the transduced population. J Neurosci 1997;17:6504-11.
28. Gimenez Y, Ribotta M, Revah F, et al. Prevention of motor neuron death by adenovirus-mediated neurotrophic factors. J Neurosci Res 1997;48:281-5.
29. Boulis N, Willmarth N, Song D, Feldman E, Imperiale M. Intraneural colchicine inhibition of adenoviral and adeno-associated viral vector remote spinal cord gene delivery. Neurosurgery 2003;52:381-7.
30. Boulis N, Bhatia V, Brindle T, et al. Adenoviral nerve growth factor and β-galactosidase transfer to spinal cord: a behavioral and histological analysis. J Neurosurg 1999;90(Suppl):99-108.
31. Liu Y, Himes B, Moul J, et al. Application of recombinant adenovirus for in vivo gene delivery to spinal cord. Brain Res 1997;768:19-29.
32. Boulis N, Bhatia V, Anlar B, Brindle T, Feldman E. Retrograde adenoviral gene delivery to rat spinal cord via sciatic nerve microinjection [abstract]. Soc Neurosci Abstr 1998;28:1308.
33. Ghadge G, Roos R, Kang U, et al. CNS gene delivery by retrograde transport of recombinant replication-defective adenoviruses. Gene Ther 1995;2:132-7.
34. Davidson B, Doran S, Shewach D, Latta J, Hartman J, Rowssler B. Expression of ecoli β-galactosidase and rat HPRT in the CNS of Macaca mulatta following adenoviral-mediated gene transfer. Exp Neurol 1994;125:258-67.
35. Durham H, Lochmuller H, Jani A, Acsadi G, Massie B, Karpati G. Toxicity of replication-defective adenoviral recombinants in dissociated culture of nervous tissue. Exp Neurol 1996;140:14-20.
36. Yang Y, Su Q, Wilson JM. Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. J Virol 1996;70:7209-12.
37. Wood M, Charlton H, Wood K, Kajiwara K, Byrnes A. Immune responses to adenovirus vectors in the nervous system. Trends Neurosci 1996;19:497-501.
38. Byrnes A, Wood M, Charlton H. Role of T cells in inflammation caused by adenovirus vectors in the brain. Gene Ther 1996;3:644-51.
39. Boulis N, Turner D, Imperiale M, Feldman E. Neuronal survival following remote adenovirus vector delivery. J Neurosurg 2002;96(Suppl):212-9.
40. Thomas C, Schiedner G, Kochanek S, Castro M, Lowenstein P. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic long-term neurological gene therapy for chronic diseases. Proc Natl Acad Sci USA 2000;97:7482-7.
41. Berns K, Hauswirth W. Adeno-associated viruses. Adv Virus Res 1979;25:407-49.
42. Srivastava A, Lusby E, Berns K. Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol 1983;45:555-64.
43. Walsh C, Liu J, Xiao X, Young N, Nienhuis A, RJ S. Regulated high level expression of a human gamma-globin gene introduced into erythroid cells by an adeno-associated virus vector. Proc Natl Acad Sci USA 1992;89:7257-61.
44. Russell D, Miller A, Alexander I. Adeno-associated virus vectors preferentially transduce cells in S phase. Proc Natl Acad Sci USA 1994;91:8915-9.
45. Flotte T, Afione S, Zeitlin P. Adeno-associated virus vector gene expression occurs in nondividing cells in the absence of vector DNA integration. Am J Respir Cell Mol Biol 1994;11:517-21.
46. Berns K, Linden R. The cryptic life style of adeno-associated virus. Bioessays 1995;17:237-45.
47. Samulski RJ, Chang L, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989;63:3822-8.
48. Kaplitt M, Leone P, Samulski R, Xiao X, Pfaff D, O'Malley K. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat Genet 1994;8:148-54.
49. Peel A, Zolotukhin S, Schrimsher G, Muzyczka N, Reier P. Efficient transduction of green fluorescent protein in spinal cord neurons using adeno-associated virus vectors containing cell type-specific promoters. Gene Ther 1997;4:16-24.
50. Klein R, Meyer E, Peel A. Neuron-specific transduction in the rat septohippocampal or nigrostriatal pathway by recombinant adeno-associated virus vectors. Exp Neurol 1998;150:183-94.
51. Mandel R, Rendahl K, Spratt S, Snyder R, Cohen L, Leff S. Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 1998;18:4271-84.
52. Davidson B, Stein C, Heth J, et al. Recombinant adeno-associated virus type 2, 4, 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA 2000;97:3428-32.
53. Chamberlin N, Du B, Lacalle SD, Saper C. Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS. Brain Res 1998;793:169-75.
54. Finkelstein R, Baughman R, Steele F. Harvesting the neural gene therapy fruit. Mol Ther 2001;3:3-7.
55. Mandel R, Rendahl K, Snyder R, Leff S. Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp Neurol 1999;159:47-64.
56. Ruitenberg M, Dijkhuizen P, Hermens W, et al. Adeno-associated viral vector-mediated gene transfer of brain-derived neurotrophic factor reverses atrophy of lesioned rubrospinal neurons [abstract]. Soc Neurosci Abstr 1999;25:497.
57. Xiao X, McCown T, Li J, Breese G, Morrow A, Samulski R. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA (A) alpha I containing receptors and increases inferior collicular seizure sensitivity. Brain Res 1997;756:76-83.
58. Stevens J. Latent herpes simplex virus and the nervous system. Curr Top Microbiol Immunol 1975;70:31-50.
59. Geller A, Breakefield X. A defective HSV-1 vector expresses Escherichia coli beta-galactosidase in cultured peripheral neurons. Science 1988;241:1667-9.
60. Geller A, Keyomarsi K, Bryan J, Pardee A. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci USA 1990;87:8950-4.
61. Glorioso J, Goins W, Meaney C, Fink D, DeLuca N. Gene transfer to brain using herpes simplex virus vectors. Ann Neurol 1994;35(Suppl):S28-34.
62. Trono D. Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther 2000;7:20-3.
63. Roe T, Reynolds T, Yu G. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993;12:2099-108.
64. von Schwedler U, Kornbluth R, Trono D. The nuclear localization signal of the matrix protein of human immunodeficiency virus type I allows the establishment of infection in macrophages and quiescent T lymphocytes. Proc Natl Acad Sci USA 1994;91:6992-6.
65. Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 1996;272:263-7.
66. Poeschla E, Won-Staal F, Looney D. Efficient transduction of nondividing human cells by feline immunodeficiency virus lentiviral vectors. Nat Med 1998;4:354-7.
67. Mitrophanous K, Yoon S, Rohl J, et al. Stable gene transfer to the nervous system using a non-primate lentiviral vector. Gene Ther 1999;6:1808-18.
68. Mazarakis N, Azzouz M, Rohll J, et al. Rabies virus glycoprotein pseudotyping of lentiviral vectors enables retrograde axonal transport and access to the nervous system after peripheral delivery. Hum Mol Genet 2001;10:2109-21.
69. Muramatsu S, Fujimoto K, Ikeguchi K, et al. Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum Gene Ther 2002;13:345-54.
70. During M, Samulski R, Elsworth J, et al. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector. Gene Ther 1998;5:820-7.
71. Sacchettoni S, Benchaibi M, Sindou M, Belin M, Jacquemont B. Glutamate-modulated production of GABA in immortalized astrocytes transduced by a glutamic acid decarboxylase-expressing retrovirus. Glia 1998;22:86-93.
72. Robert J, Bouilleret V, Ridoux V, et al. Adenovirus-mediated transfer of a functional GAD gene into nerve cells: potential for the treatment of neurological disease. Gene Ther 1997;4:1237-45.
73. Mi J, Chatterjee S, Wong K, AJ C, Lawless G, Tobin. Recombinant adeno-associated virus (AAV) drives constitutive production of glutamate decarboxylase in neural cell lines. J Neurosci Res 1999;57:137-48.
74. During M, Kaplitt M, Stern M, Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 2001;12:1589-91.
75. Luo J, Kaplitt M, Fitzsimons H, et al. Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 2002;298:425-9.
76. Kimura H, Kuriyama K. Distribution of gamma-aminobutyric acid (GABA) in the rat hypothalamus: functional correlates of GABA with activities of appetite controlling mechanisms. J Neurochem 1975;24:903-7.
77. Kelly J, Alheid G, Newberg A, Grossman S. GABA stimulation and blockade in the hypothalamus and midbrain: effects on feeding and locomotor activity. Pharmacol Biochem Behav 1977;7:537-41.
78. Rattan A, Mangat H. Electrical activity and feeding correlates of intracranial hypothalamic injection of GABA, muscimol and picrotoxin in the rats. Acta Neurobiol Exp 1990;50:23-36.
79. Bennett G, Xie Y. A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 1988;33:87-107.
80. Kuriyama S, Mitoro A, Tsujinoue H, et al. Particle-mediated gene transfer into murine livers using a newly developed gene gun. Gene Ther 2000;7:1132-6.
81. Lu C, Chou A, Wu C, et al. Gene-gun particle with pro-opiomelanocortin cDNA produces analgesia against formalin-induced papin in rats. Gene Ther 2002;9:1008-14.
82. Yao M, Wang J, Gu J, et al. Interleukin-2 gene has superior antinociceptive effects when delivered intrathecally. Neuroreport 2002;13:791-4.
83. Yao M, Gu J, Wang J, et al. Interleukin-2 gene therapy of chronic neuropathic pain. Neuroscience 2002;112:409-16.
84. Finegold A, Mannes A, Iadarola M. A paracrine paradigm for in vivo gene therapy in the central nervous system: treatment of chronic pain. Hum Gene Ther 1999;10:1251-7.
85. Wilson S, Yeomans S, Bender M, Lu Y, Goins W, Glorioso J. Antihyperalgesic effects of infection with a preproenkephalin-encoding herpes virus. Proc Natl Acad Sci USA 1999;96:3211-6.
86. Goss J, Mata M, Goins W, Wu H, Glorioso J, Fink D. Antinociceptive effect of a genomic herpes simplex virus-based vector expressing human proenkephalin in rat dorsal root ganglion. Gene Ther 2001;8:551-6.
87. Turner D, Noordmans A, Feldman E, Boulis N. Remote adenoviral gene delivery to the spinal cord: contralateral delivery and reinjection. Neurosurgery 2001;48:1309-16.
88. Yoshimura N, Franks M, Sasaki K, et al. Gene therapy of bladder pain with herpes simplex virus (HSV) vectors expressing preproenkephalin (PPE). Urology 2001;57(Suppl 1):116.
89. Braz J, Beaufour C, Coutaux A, et al. Therapeutic efficacy in experimental polyarthritis of viral-driven enkephalin overproduction in sensory neurons. J Neurosci 2001;21:7881-8.
90. Ishii K, Isono M, Inoue R, Hori S. Attempted gene therapy for intractable pain: dexamethasone-mediated exogenous control of beta-endorphin secretion in genetically modified cells and intrathecal transplantation. Exp Neurol 2000;166:90-8.
91. Eaton M, Karmally S, Martinez M, Plunkett J, Lopez T, Cejas P. Lumbar transplant of neurons genetically modified to secrete galanin reverse pain-like behaviors after partial sciatic nerve injury. J Peripher Nerv Syst 1999;4:245-57.
92. Hagihara Y, Saitoh Y, Arita N, et al. Long-term functional assessment of encapsulated cells transfected with tet-on system. Cell Transplant 1999;8:431-4.
93. Beutler A, Banck M, Bach F, et al. Retrovirus-mediated expression of an artificial beta-endorphin precursor in primary fibroblasts. J Neurochem 1995;64:475-81.
94. Sud V. Nerve entrapment and gene therapy. J Long-Term Effects Med Implant 2002;12:97-104.
95. McDaniel D. DNA-transfer approaches in treatment of chronic inflammatory joint disease. J Long-Term Effects Med Implant 2002;12:71-84.
96. Chen S, Wilson J, Vallance D, Hartman J, Davidson B, Roessler B. A recombinant adenoviral vector expressing a soluble form of VCAM-1 inhibits VCAM-1/VLA-4 adhesion in transduced synoviocytes. Gene Ther 1995;2:469-80.
97. Roessler B, Hartman J, Vallance D, Latta J, Janich S, Davidson B. Inhibition of interleukin-1-induced effects in synoviocytes transduced with the human IL-1 receptor antagonist cDNA using an adenoviral vector. Hum Gene Ther 1995;6:307-16.
98. Sandhu H, Anderson D, Andersson G, et al. Summary statement: alternative delivery by gene therapy and cost justification of bone morphogenetic proteins for spine fusion. Spine 2002;27 (Suppl 1):S86.
99. Dabrosin C, Gyorffy S, Margetts P, Ross C, Gauldie J. Therapeutic effect of angiostatin gene transfer in a murine model of endometriosis. Am J Pathol 2002;161:909-18.
100. MacDermot J, MacDermot K. Neuropathic pain in Anderson-Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001;429:121-5.
101. Janson C, McPhee S, Bilaniuk L, et al. Clinical protocol. Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain. Hum Gene Ther 2002;13:1391-412.
102. Romero M, Rangappa N, Garry M, Smith G. Functional regeneration of chronically injured sensory afferents into adult spinal cord after neurotrophin gene therapy. J Neurosci 2001;21:8408-16.
103. Paxinos G, Watson C. Rat brain in stereotaxic coordinates. 4th edition. New York: Academic Press; 1998.